ESMO Congress, CURE® spoke with an expert about Fotivda and certain challenges patients may experience, such as side effects.

Researchers from the universities of Zurich, Yale and Harvard reveal the differences between the characteristics of the ...

HANSIZHUANG (serplulimab) is the world's first anti-PD-1 mAb for first-line treatment of ES- SCLC - HANSIZHUANG (serplulimab) is expected to become the first and only anti-PD-1 mo ...

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every ...